Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isophane insulin added to basal-bolus insulin for dexamethasone-induced hyperglycaemia in hospitalized patients with COVID-19 and diabetes
ACTRN12621001340820Phase 4Terminated
- Sponsor
- Prof NW Cheung
- Start
- Nov 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hyperglycemia, type 2 diabetes mellitus (T2DM) and coronavirus disease 2019 (COVID-19) comparing Morning isophane insulin + basal-bolus insulin with Basal-bolus insulin alone (2 arms). Primary endpoint: Mean daily glucose level during the trial. Started Nov 2021; status: terminated.
02
Drugs
insulin isophanehuman insulin
03
Conditions
hyperglycemiatype 2 diabetes mellitus (T2DM)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on ACTRN12621001340820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001340820.